Brett A. Schulman

Brett Schulman

Associate

Brett Schulman is an associate in the New York office of Wilson Sonsini Goodrich & Rosati, where he is a member of the firm’s corporate practice. His work focuses on corporate and securities transactions within the life sciences, healthcare, and technology sectors. Brett has experience representing public and private companies and has assisted with matters ranging from formation and early-stage venture financing to listings of publicly traded securities on U.S. exchanges. In addition, he has counseled privately and publicly held companies on general corporate governance matters.

Prior to joining the firm, Brett worked at JPMorgan Chase as a Vice President, Senior KYC Officer in New York, conducting due diligence on life sciences, healthcare, and technology companies.

Experience

Prior to joining the firm, Brett worked at JPMorgan Chase as a Vice President, Senior KYC Officer in New York, conducting due diligence on life sciences, healthcare, and technology companies.

Education

J.D., The George Washington University Law School, 2015
B.A., Politics, New York University, 2012Minor in Philosophy; University Honors Scholar

Admissions

State Bar of New York

Credentials

Education

J.D., The George Washington University Law School, 2015
B.A., Politics, New York University, 2012Minor in Philosophy; University Honors Scholar

Admissions

State Bar of New York

Recent Insights

Client Highlights

On August 31, 2026, PMV Pharmaceuticals, a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced the pricing of an underwritten public offering consisting of 22,055,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 19,900,000 shares of its common stock, as well as accompanying warrants to purchase an aggregate of 41,955,000 shares of common stock. The combined public offering price of each share of common stock and accompanying warrant is $1.21. The gross proceeds from the offering, before deducting underwriting discounts, commissions, offering expenses, and any exercise of the warrants, are expected to be approximately $50.8 million. Wilson Sonsini Goodrich & Rosati advised PMV Pharma on the transaction.

Learn More

Client Highlights

On March 24, 2026, Spade, the data and AI platform transforming how financial institutions use transaction data, announced $40 million in Series B funding. The round was led by Oak HC/FT, with participation by Andreessen Horowitz, Flourish, Gradient, NAventures, National Bank of Canada’s corporate venture arm, and Y Combinator. Wilson Sonsini Goodrich & Rosati advised Spade on the transaction.

Learn More